TABLE 3

Individual percentage of GSK2251052-related components in human excreta (0-120 hours) after a single i.v. dose of 1500 mg of [¹⁴C]GSK2251052

Metabolite	% Administered Dose Recovered in Each Subject
Metabolite	101	102	103	104	105	106	Mean ± S.D.
Urine^{^a}
GSK2251052	27.8	31.6	32.4	23.3	27.9	30.4	28.9 ± 3.0
M1	BQL	BQL	BQL	BQL	BQL	BQL	BQL ± NC
M2	BQL	BQL	BQL	BQL	BQL	BQL	BQL ± NC
M3^{^b}	44.7	42.6	43.8	41.0	39.3	51.6	43.8 ± 3.9
M7	BQL	BQL	BQL	BQL	BQL	BQL	BQL ± NC
Total quantified	72.5	74.2	76.2	64.4	67.3	82.0	72.8 ± 5.8
Total radioactivity	84.1	83.2	86.6	80.8	77.4	86.4	83.1 ± 3.2
Feces
M1	1.2	1.3	1.1	2.3	0.8	1.8	1.4 ± 0.5
M3	2.6	4.7	2.7	3.3	3.1	3.3	3.3 ± 0.7
Total quantified	3.9	6.0	3.8	5.5	3.9	5.1	4.7 ± 0.9
Total radioactivity	4.7	7.4	5.4	6.9	5.7	5.9	6.0 ± 0.9

BQL, below quantification limit; NC, not calculated.
↵^a 120–336-hour urine samples from each subject were pooled proportionally by sample weight, and equal volumes of each pool were combined to produce a single composite sample.
↵^b M3 (5.9% of dose) was the only component detected in the composite sample.